French biopharmaceutical company ERYTECH has completed the enrolment of patients for its Phase IIb trial of eryaspase to treat acute myeloid leukemia (AML).

Eryaspase, also known as GRASPA, consists of the L-asparaginase enzyme found inside the donor-derived red blood cells based on ERYTECH’s proprietary ERYCAPS technology platform.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The enzyme attacks asparagine, an amino acid considered responsible for the growth and multiplication of the tumour cells that starves and eventually kills the cancer cells.

The Phase IIb trial has been designed as an open-label, randomised, multi-centre study intended to determine the efficacy of eryaspase in addressing acute leukemia and other unmet oncological diseases.

"The primary goal of the trial is to determine the overall survival (OS) following the administration of eryaspase."

A total of 123 patients aged 65 and above who have been recently diagnosed with AML and are unable to receive intensive chemotherapy have been enrolled in the trial.

See Also:

The primary goal of the trial is to determine the overall survival (OS) following the administration of eryaspase.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

ERYTECH CEO and chairman Gil Beyen said: “AML is a very aggressive cancer. We are developing eryaspase with the goal of contributing to the treatment of these patients, many of whom may respond to L-asparaginase, but have difficulty with the side effects associated with the current available forms.

“Therefore, we believe the increased tolerability profile obtained through the encapsulation of L-asparaginase in the red blood cells could result in a new innovative approach to treatment of AML patients.”

The company is also undertaking the Phase I clinical trial of eryaspase in the US in adults with newly diagnosed acute lymphoblastic leukemia (ALL).

It is also exploring options of the usage of eryaspase for solid tumours and metastatic pancreatic cancer.